Home › Spinal Muscular Atrophy › Iowa › Cedar Rapids
Spinal Muscular Atrophy clinical trials in Cedar Rapids, IA
3 studies for Spinal Muscular Atrophy are looking for participants at sites in and around Cedar Rapids (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
RecruitingPhase 2
- University of Iowa Stead Family Children's Hospital, Iowa City · 25 mi away
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RecruitingPhase 2
- University of Iowa, Iowa City · 25 mi away
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
RecruitingObservational study
- University of Iowa, Iowa City · 25 mi away
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) attacks nerve cells in the spinal cord, weakening voluntary muscles. Read about the genetics, types, and what may help.
More about Spinal Muscular Atrophy on MedlinePlus
Spinal Muscular Atrophy trials in other cities
- Mountain View, CA9 studies
- New York City, NY8 studies
- Boston, MA7 studies
- Norfolk, VA6 studies
- Philadelphia, PA6 studies
- Houston, TX5 studies
- Chicago, IL5 studies
- Phoenix, AZ4 studies
- Grand Rapids, MI4 studies
- Lewisville, TX4 studies
- Baltimore, MD3 studies
- Charlottesville, VA3 studies
Other studies in Cedar Rapids
- Non-Small Cell Lung Cancer23 studies
- Breast Cancer17 studies
- Cancer (all types)17 studies
- Lung Cancer17 studies
- Multiple Myeloma16 studies
- Acute Myeloid Leukemia15 studies
- Colorectal Cancer14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Prostate Cancer12 studies
- Melanoma11 studies
- Metastatic Cancer9 studies
- Blood Cancers9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.